Citations

Clear

3042 citation(s) found for "Kumar, S".

Utility of MRI and CT in Sports Cardiology
Kumar, Vinayak , Domènech-Ximenos, Blanca , Francone, Marco , Allison, Thomas G. , Rajiah, Prabhakar , Kumar, Vinayak , Domenech-Ximenos, Blanca , Francone, Marco , Broncano, Jordi, Rajiah, Prabhakar , Broncano, Jordi

Mayo Clinic

RadioGraphics | February 27, 2025 | Volume: 45 | Issue: 3 | Pages: No page available

10.1148/rg.240045 | PMID 40014471 Get It

MRI and CT play an important role in sports cardiology, including preparticipation evaluation, distinguishing adaptive changes of athlete’s heart from pathologic entities, and evaluation following cardiovascular symptoms or adverse events.
Development of a Core Critical Care Data Dictionary With Common Data Elements to Characterize Critical Illness and Injuries Using a Modified Delphi Method
Anderson, Wesley R., Heavner, Smith H., Al-Hakim, Tamara, Cruz‐Cano, Raul , Engel, Heidi J., Lamb, Keith, MacLaren, Robert , Rincon, Teresa , Sikora, Andrea, Tanner, Donna, Teeter, William , Wong, An-Kwok Ian , Zhang, Xiaohan Tanner , Zimmerman, Jerry J. , Kumar, Vishakha K. , Cobb, J. Perren, Laudański, Krzysztof , Murphy, David J., Anderson, Wesley, Heavner, Smith H., Kamaleswaran, Rishikesan , Badawi, Omar , Grunwell, Jocelyn R. , Herasevich, Vitaly , Khanna, Ashish K. , Sanchez-Pinto, Lazaro Nelson , Sikora, Andrea , Stevens, Robert David , Wynn, James Lawrence , Reuter‐Rice, Karin

Mayo Clinic

Critical Care Medicine | February 21, 2025 | Volume: 53 | Issue: 5 | Pages: e1045-e1054

10.1097/ccm.0000000000006595 | PMID 39982128 Get It

OBJECTIVES: To develop the first core Critical Care Data Dictionary (C2D2) with common data elements (CDEs) to characterize critical illness and injuries. DESIGN: Group consensus process using modified Delphi approach. SETTING: Electronic surveys and in-person meetings. SUBJECTS: A multidisciplinary workgroup of clinicians and researchers with expertise in the care of the critically ill and injured. INTERVENTIONS: The Delphi process was divided into domain and CDE portions with each composed of two item generation rounds and one item reduction/refinement rounds. Two in-person meetings augmented this process to facilitate review and consideration of the domains and by panel members. The final set of domains and CDEs was then reviewed by the group to meet the competing criteria of utility and feasibility, resulting in the core dataset. MEASUREMENTS AND MAIN RESULTS: The 23-member Delphi panel was provided 1833 candidate variables for potential dataset inclusion. The final dataset includes 226 patient-level CDCs in nine domains, which include anthropometrics and demographics (8), chronic comorbid illnesses (18), advanced directives (1), ICU diagnoses (61), diagnostic tests (42), interventions (27), medications (38), objective assessments (26), and hospital course and outcomes (5). Upon final review, 91% of the panel endorsed the CDCs as meeting criteria for a minimum viable data dictionary. Data elements cross the lifespan of neonate through adult patients. CONCLUSIONS: The resulting C2D2 provides a foundation to facilitate rapid collection, analyses, and dissemination of information necessary for research, quality improvement, and clinical practice to optimize critical care outcomes. Further work is needed to validate the effectiveness of the dataset in a variety of critical care settings.
Comparison of Sagittal Plane Correction With “Bullet” Versus “Banana” Type Transforaminal Lumbar Interbody Fusion Devices
Pennington, Zach , Hamouda, Abdelrahman M. , Martini, Michael L. , Kumar, Rahul , Mikula, Anthony L. , Potes, Maria Astudillo , Bydon, Mohamad , Clarke, Michelle J. , Krauss, William E. , Nassr, Ahmad , Freedman, Brett A. , Sebastian, Arjun S. , Fogelson, Jeremy L. , Elder, Benjamin D. , Hamouda, Abdelrahman , Martini, Michael , Pennington, Zach , Nassr, Ahmad N , Clarke, Michelle J , Kumar, Rahul , Freedman, Brett A.

Mayo Clinic

Operative Neurosurgery | February 20, 2025 | Volume: 29 | Issue: 5 | Pages: 624-632

10.1227/ons.0000000000001518 | PMID 39976442 Get It

BACKGROUND AND OBJECTIVES: Transforaminal lumbar interbody fusion (TLIF) allows for direct and indirect decompression and segmental lordosis in sagittal plane correction. This study compares the effectiveness of “Bullet” type and “Banana” type devices for sagittal plane correction. METHODS: Patients who underwent 1-level or 2-level TLIF for degenerative pathology at a single tertiary care center were identified. Details were extracted on demographics, interbody dimensions, and preoperative and postoperative lumbopelvic parameters from upright radiographs. Cages were categorized as “Bullet” or “Banana” type based on morphology and manufacturer description of optimal position. Univariable comparisons between levels treated with “Bullet” and “Banana” type interbodies were performed. Multivariable linear regression was performed to identify independent predictors of postoperative segmental lordosis and change in segmental lordosis. RESULTS: One hundred and ninety eight unique patients (median 66.6 years; [IQR 59.5, 73.7]; 56.6% female) were included with 241 levels treated, of which 114 (52.7%) were treated with “Banana” type interbodies and 127 (47.3%) with “Bullet” type. “Banana” type interbodies afforded both greater postoperative segmental lordosis (8.1 [6.2, 10.7] vs 7.5 [5.2, 9.6]; P = .048) and greater increase in segmental lordosis (3.3 [0.7, 7.0] vs 2.3 [0.1, 4.2]; P = .015). On multivariable linear regression, only preoperative segmental lordosis (β = 0.322 per degree; [0.244, 0.399]; P < .001), implant listed lordosis (β = 0.146 per degree; 95% CI [0.048, 0.244]; P = .004), preoperative pelvic incidence (0.072 per degree; [0.034, 0.111]; P < .001), and use of bilateral TLIF windows (β = 3.133; [1.213, 5.053]; P = .001) were predictive of postoperative segmental lordosis. CONCLUSION: The present analysis suggests that baseline lumbopelvic anatomy, interbody lordosis, and the use of bilateral TLIF windows are the most important predictors of postoperative segmental lordosis. Use of “Banana” vs “Bullet” type interbodies was not predictive of segmental lordosis achieved on immediate postoperative upright radiographs. Further work is merited to determine whether the 2 interbody types demonstrate differences regarding subsidence risk or maintenance of correction.
Comparison Between Dynamic Models for Predicting Response to Corticosteroids in Alcohol‐Associated Hepatitis: A Global Cohort Study
Idalsoaga, Francisco , Díaz, Luis Antonio , Guizzetti, Leonardo , Dunn, Winston , Arnold, Jorge , Ayares, Gustavo , Mortuza, Rokhsana , Mahli, Gurpreet, Islam, Alvi H. , Maiwall, Rakhi , Qian, Steve , Elfeki, Mohamed A. , Ramírez, Carolina , Higuera‐de‐la‐Tijera, Fátima , Al‐Karaghouli, Mustafa , Jalal, Prasun K. , Ibrahim, Mohamad Ali , García‐Tsao, Guadalupe , Havaj, Daniel Ján , Sulejova, Karolina, Shah, Vijay H. , Kamath, Patrick S. , Mehta, Heer , Arnold, Jorge , Ayares, Gustavo , Mortuza, Rokhsana , Sarin, Shiv Kumar , Maiwall, Rakhi , Qian, Steve , Simonetto, Douglas A , Singal, Ashwani K , Elfeki, Mohamed A , Ramirez-Cadiz, Carolina , Cabezas, Joaquín , Ventura Cots, Meritxell , Higuera-De La Tijera, Fatima , Abraldes, Juan G , Jalal, Prasun K , García-Tsao, Guadalupe , Skladaný, Lubomir , Havaj, Daniel J , Kamath, Patrick S , Arrese, Marco , Bataller, Ramon A , Arab, Juan P , Guizzetti, L , Díaz, Luis A , Dunn, Winston , Echavaría, Victor , Zhang, Wei , Simonetto, Douglas A. , Singal, Ashwani K. , Cabezas, Joaquín , Ventura‐Cots, Meritxell , Abraldeṣ, Juan G. , García–Tsao, Guadalupe , Goyes, Daniela , Selčanová, Světlana Adamcová , Rincón, Diego , Arrese, Marco , Arab, Juan Pablo

Mayo Clinic

Alimentary Pharmacology & Therapeutics | February 19, 2025 | Volume: 61 | Issue: 8 | Pages: 1391-1395

10.1111/apt.70024 | PMID 39967231 Get It

ABSTRACTSeveral dynamic models predict mortality and corticosteroid response in alcohol‐associated hepatitis (AH), yet no consensus exists on the most effective model. This study aimed to assess predictive models for corticosteroid response and short‐term mortality in severe AH within a global cohort. We conducted a multi‐national study of patients with severe AH treated with corticosteroids for at least 7 days, enrolled between 2009 and 2019. Dynamic models—Lille‐4, Lille‐7, trajectory of serum bilirubin (TSB), and neutrophil‐to‐lymphocyte ratio (NLR)—were used to estimate 30‐ and 90‐day mortality. Lille‐7 demonstrated the highest accuracy for both 30‐ and 90‐day mortality.
Metastasis-directed therapy (MDT) plus androgen deprivation therapy (ADT) for oligometastatic prostate cancer (omPC): Primary results of the EXTEND continuous ADT (cADT) basket plus combined analysis with the updated intermittent ADT (iADT) basket and immu
Fellman, Bryan , Mayo, Lauren L. , Choi, Seungtaek , Phillips, Ryan, Deek, Matthew P. , Zurita, Amado J. , Siddiqui, Bilal A. , Tang, Chad , Sherry, Alexander D. , Haymaker, Cara , Bathala, Tharakeswara K , Medina-Rosales, Marina N , Liu, Suyu , Chun, Stephen G. , Aparicio, Ana M , Pilie, Patrick Glen , Siddiqui, Bilal A , Subudhi, Sumit Kumar , Reuben, Alexandre , Corn, Paul Gettys , Tran, Phuoc T , Tang, Chad

Mayo Clinic

Journal of Clinical Oncology | February 18, 2025 | Volume: 43 | Issue: 5_suppl | Pages: 140-140

10.1200/jco.2025.43.5_suppl.140 Get It

140 Background: In the phase II EXTEND iADT omPC basket, MDT+iADT improved progression-free survival (PFS) vs iADT. Here we present the primary results of the EXTEND cADT omPC basket. We further report a pre-specified combined analysis with updated results from the iADT basket and examine the effects of MDT on immunity. Methods: Patients with 1 to 5 omPC metastases were randomized 1:1 to MDT+cADT vs cADT (NCT03599765). MDT consisted of definitive local therapy. cADT consisted of ADT +/- second-generation anti-androgens. The primary endpoint was per-protocol PFS, defined by biochemical criteria (Prostate Cancer Working Group 3), radiologic measures (RECIST v1.1), clinical progression, or death. 87 patients were needed to show superiority at a one-sided P of 0.10 by log-rank test. CDR3 regions in rearranged T cell receptor (TCR) β-chains from pre- and post-enrollment peripheral blood were sequenced with immunoSEQ (Adaptive Biotech). TCR repertoire modulation was defined as having TCR expansion plus contraction using a false-discovery-corrected betabinomial model. TCR sequencing from the ORIOLE trial (NCT02680587) was assessed for external validation. Results: From 2018 to 2022, 87 randomized patients were treated per protocol (MDT+cADT: 45; cADT: 42). 39% had castrate resistant omPC. MDT was definitive radiotherapy in all cases. With median follow-up of 31 mo, median PFS was 47 mo after MDT+cADT vs 22 mo after cADT (HR 0.50; 95% CI 0.23 to 1.08; one-sided P = 0.036). In the combined analysis (N=174) with median follow-up of 42 mo, MDT+ADT improved PFS (HR 0.45; 95% CI 0.30 to 0.69; P < 0.001), radiologic PFS (HR 0.63; 95% CI 0.40 to 0.97; P = 0.038), and castration-resistance free-survival (HR 0.40; 95% CI 0.19 to 0.82; P = 0.013). MDT+ADT had higher odds of TCR repertoire modulation vs ADT (55% vs 15%, P < 0.001). This finding was validated in the ORIOLE trial (MDT: 57% vs observation: 19%, P = 0.03). Among the subset of patients with extreme responses, random forest modeling of 37 clinical/immune variables identified TCR repertoire modulation as the variable with highest importance; further, MDT+ADT induced TCR repertoire modulation in all patients with favorable responses (i.e. PFS > 4 years) and none with unfavorable responses (i.e. PFS < 1 year). Among all patients randomized to MDT+ADT, TCR repertoire modulation was associated with longer PFS (HR 0.21; 95% CI 0.06 to 0.76; P = 0.02). Conclusions: MDT+cADT met the PFS primary endpoint of the phase II EXTEND trial, warranting phase III testing. From the combined analysis, MDT+ADT may also improve longer term outcomes including radiologic PFS and castration-resistance-free survival. Improved outcomes may result from MDT-induced immunomodulation, with implications for future trial design. Clinical trial information: NCT03599765 .
High‐Throughput Immunoassays for Cavin‐4 IgG: A Diagnostic Tool for Immune‐Mediated Rippling Muscle Disease
LaFrance‐Corey, Reghann G., Kherbek, Haidara , Harinesan, Nimalan, Milone, Margherita , Sarker, Pallab , Karsten, Carley , Dasari, Surendra , Litchy, William J. , Pittock, Sean J. , Mills, John R. , Dubey, Divyanshu , Dubey, Divyanshu , Pittock, S J , Paramasivan, Naveen K, Knight, Andrew M, Liewluck, Teerin , Dubey, Divyanshu , Dubey, Divyanshu , Kherbek, Haidara , Paramasivan, Naveen Kumar , Knight, Andrew M.

Mayo Clinic

Annals of Clinical and Translational Neurology | February 17, 2025 | Volume: 12 | Issue: 4 | Pages: 876-880

10.1002/acn3.70012 | PMID 39957412 Get It

ABSTRACTCavin‐4 was identified as a potential autoantigen for immune‐mediated rippling muscle disease (iRMD). To validate this, we developed and tested various immunoassays, including a cell‐based assay (CBA), cavin‐4 recombinant protein ELISA, and multi‐peptide ELISA. Among 19 iRMD patients, all exhibited muscle rippling, and 13 had percussion‐induced mounding. All immunoassays demonstrated clinical and analytical specificities greater than 95%. The protein ELISA had the highest sensitivity (94.7%) and specificity (99.9%), outperforming CBA (sensitivity 89.5%, specificity 99.6%) and the multi‐peptide ELISA (sensitivity 79.0%, specificity 97.2%). Our results suggest that the cavin‐4 protein ELISA is a promising tool for high‐throughput clinical testing in iRMD.
Sustained Improvement in Health‐Related Quality of Life in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient‐Reported Outcomes
Plesner, Torben , Kumar, Shaji, Hulin, Cyrille , Orlowski, Robert Z. , Nahi, Hareth , Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand , Gupta‐Werner, Niodita , Kaila, Shuchita, Pei, Huiling , Matt, Kathryn, Gries, Katharine S. , Carson, Robin, Borgsten, Fredrik, Nahi, Hareth , Roussel, Murielle , Arnulf, Bertrand , Orlowski, Robert Z. , Perrot, Aurore , Facon, Thierry T.F. , Usmani, Saad Z. , Kumar, Shaji , Bahlis, Nizar Jacques , Mollee, Peter , Ramasamy, Karthik , Roussel, Murielle , Jaccard, Arnaud , Karlin, Lionel , Chari, Ajai , Wang, George C. , Weisel, Katja C

Mayo Clinic

European Journal of Haematology | February 14, 2025 | Volume: 114 | Issue: 5 | Pages: 883-889

10.1111/ejh.14392 | PMID 39952901 Get It

ABSTRACTObjectivesThis final post hoc analysis evaluated patient‐reported outcomes from the Phase 3 MAIA study of daratumumab, lenalidomide, and dexamethasone (D‐Rd) versus lenalidomide and dexamethasone (Rd) after median 64.5‐month follow‐up in transplant‐ineligible patients with newly diagnosed multiple myeloma (NDMM), including patient subgroups.MethodsKey scales from the EORTC QLQ‐C30 (global health status [GHS], physical functioning, pain, and fatigue) were assessed. Scores were evaluated every 3 months for 1 year, then every 6 months until disease progression.ResultsThe intent‐to‐treat population (n = 737) included 46.3% frail, 35.4% 70 to < 75 years old, and 43.6% ≥ 75 years old. D‐Rd‐treated patients showed improvements from baseline that were sustained over 5 years in the intent‐to‐treat population and across subgroups by age, frailty, and bone lesions. Greater proportions of patients treated with D‐Rd versus Rd achieved minimally important changes for improvement at cycle 36 (year ~3) in GHS (odds ratio, 1.84 [95% CI, 1.16–2.91]), physical functioning (1.93 [1.18–3.14]), pain (1.41 [0.90–2.22]), and fatigue (2.00 [1.24–3.23]). Greater proportions of patients with bone lesions improved with D‐Rd versus Rd on GHS and physical functioning.ConclusionsIn transplant‐ineligible patients with NDMM, D‐Rd improved health‐related quality of life over a 5‐year period versus Rd. Trial Registration: ClinicalTrials.gov: NCT02252172
Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials
Shi, Qian , Paiva, Bruno , Pederson, Levi , Dimier, Natalie , Talpes, Ela, Prior, Thomas J. , Órfão, Alberto , Sonneveld, Pieter , Kumar, Shaji , Patel, Reshma, Bartlett, Blake, Schecter, Jordan M. , Seckinger, Anja , D’Agostino, Mattia , Goldschmidt, Hartmut , Owen, Roger G., Durie, Brian G.M. , Munshi, Nikhil C. , Group, on behalf of the International Independent Team for Endpoint Approval of Myeloma Minimal Residual Disease (i2TEAMM), Pederson, Levi D , Moreau, Philippe , Sonneveld, Pieter , Kumar, Shaji K , Dixon, Jesse G. , McCarthy, Phillip , Hose, Dirk , Seckinger, Anja , Mattia, D'Agostino , Goldschmidt, Hartmut , Oliva, Stefania , Anderson, Kenneth C , San-Miguel, Jesus , Munshi, Nikhil C , Shi, Qian , Paiva, Bruno , Orfao, Alberto , Moreau, Philippe , Patel, Reshma, McCarthy, Philip L. , Hose, Dirk , Oliva, Stefania , Anderson, Kenneth C. , Miguel, Jesús F. San , Group, on behalf of the International Independent Team for Endpoint Approval of Myeloma Minimal Residual Disease (i2TEAMM)

Mayo Clinic

Journal of Clinical Oncology | February 12, 2025 | Volume: 43 | Issue: 11 | Pages: 1289-1301

10.1200/jco-24-02020 | PMID 39938021 Get It

PURPOSE Newly approved drugs and combinations treating multiple myeloma (MM) have resulted in substantial improvements in patients' survival. To deliver rapid access to newer therapies, an earlier end point to expedite clinical trials is needed. Our objective was to evaluate the minimal residual disease–negative complete response (MRD-CR) as an intermediate end point for progression-free survival (PFS) and overall survival (OS) in newly diagnosed (ND) transplant-eligible (NDTE) patients, ND transplant-ineligible (NDTinE) patients, and patients with relapsed/refractory (RR) MM. PATIENTS AND METHODS Individual patient data from 20 randomized multicenter trials were collected. Eleven studies (4,773 patients) with sufficient data were analyzed to evaluate whether 9- or 12-month MRD-CR classified at a 10 –5 threshold could be reasonably likely to predict the clinical benefit of new agents regarding PFS and OS. Global odds ratio (OR) was estimated using the bivariate Plackett Copula model. Supportive evaluation included correlations of the treatment effects on MRD-CR end points and PFS/OS, evaluated by both linear regression ( R 2 weighted least squared ) and Copula ( R 2 Copula ) models. RESULTS The analysis demonstrated that both 9- and 12-month MRD-CR strongly correlated with PFS at patient level in NDTE patients, NDTinE patients, and patients with RRMM. Global ORs ranged from 3.06 to 16.24, all with 95% CIs excluding 1.0. Encouraging trial-level correlations ( R 2 , 0.61-0.70) were observed by pooling three populations and were stronger ( R 2 , 0.67-0.78) in the ND population. Similar results were observed for OS. CONCLUSION Our findings provided the support for use of MRD-CR classified at a 10 –5 threshold at either 9 or 12 months after starting of the treatment, as an intermediate end point to support accelerated approvals, in future trials in NDTE patients, NDTinE patients, and patients with RRMM.